Overview

• Eli Lilly has halted orders to UK wholesalers until 1 September to manage unprecedented demand ahead of a list‑price increase.
• The list price is set to rise by about 170%, taking the highest dose from £122 to £330, with confirmed discounts expected to reduce the top dose to about £247.50 at participating providers.
• Major chains including Boots, Lloyds and Superdrug report intermittent or exhausted stocks, with many pharmacies prioritising existing patients, pausing new starts or limiting quantities.
• Lilly says NHS pricing is unchanged, though access remains limited in practice, with Sky News reporting only eight of 42 Integrated Care Boards currently offering the treatment.
• Pharmacy bodies and regulators warn against stockpiling and turning to unregulated sellers, citing MHRA enforcement and recent Border Force seizures of fake weight‑loss pens.